ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cells-Reference-Cited by-同舟云学术

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cells

Published:2013-03 Issue:3 Volume:2 Page:e23185
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Faget Julien,Sisirak Vanja,Blay Jean-Yves,Caux Christophe,Bendriss-Vermare Nathalie,Ménétrier-Caux Christine

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/onci.23185

Reference10 articles.

1. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2. Tumor Immunotherapy Directed at PD-1

3. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

4. Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

5. Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition;Frontiers in Bioscience-Landmark;2024-08-20

2. Multiomics analysis of homologous recombination deficiency across cancer types;Biomolecules and Biomedicine;2024-07-28

3. Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling;Journal of Experimental & Clinical Cancer Research;2024-07-17

4. The Multifaceted Functionality of Plasmacytoid Dendritic Cells in Gastrointestinal Cancers: A Potential Therapeutic Target?;Cancers;2024-06-13

5. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03